List of works - David Preiss

A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design

scientific article published on January 2011

Ambient temperature and pseudohyperkalaemia

scientific article published on 01 July 2006

Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future

scientific article

Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes

scientific article published on 3 August 2016

Biochemistry laboratories should routinely report non-HDL-cholesterol

scientific article published on 17 June 2015

Body Mass Index and Risk of Nonalcoholic Fatty Liver Disease: Two Electronic Health Record Prospective Studies

scientific article published on 16 December 2015

Cardiac Troponin T and Troponin I in the General Population

scientific article published on 24 April 2019

Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies?

scientific article published on 03 July 2017

Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study

scientific article published on 19 June 2014

Choice of medical therapy to lower triglycerides in those at risk of pancreatitis

scientific article published in December 2013

Cholesterol- and blood-pressure-lowering drug use for secondary cardiovascular prevention in 2004-2013 Europe

scientific article published on 31 October 2016

Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week

article

Classification of reported statin intolerance

Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ej

scientific article published on 04 January 2017

Combined Free Light Chains Are Novel Predictors of Prognosis in Heart Failure.

scientific article

Combined cardiovascular and diabetes risk assessment in primary care

scientific article published on 01 January 2011

Comparison between High-Sensitivity Cardiac Troponin T and Cardiac Troponin I in a Large General Population Cohort

scientific article published on 20 August 2018

Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.

scientific article

Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction

scientific article

Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up

scientific article published on 30 September 2014

Diabetic microvascular complications as simple indicators of risk for cardiovascular outcomes and heart failure

scientific article published on 20 May 2016

Diagnosing unsuspected hypopituitarism in adults from suggestive thyroid function test results

scientific article

Do statins reduce microvascular complications in diabetes?

scientific article published on 09 September 2014

Does the LDL Receptor Play a Role in the Risk of Developing Type 2 Diabetes?

scientific article published in The Journal of the American Medical Association

Effect of Evolocumab on Lipoprotein Particles

scientific article published on 8 November 2017

Effect of Rosuvastatin on Fatigue in Patients With Heart Failure

article

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

scientific article

Effect of metformin therapy on circulating amino acids in a randomized trial: the CAMERA study

scientific article published on 16 February 2016

Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis

scientific article

Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus

scientific article published on 31 July 2017

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia

scientific article published on 30 May 2016

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial

scientific article published on 03 April 2016

Emerging therapeutic approaches to treat dyslipidemia

scientific article published on July 2014

Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).

scientific article published on 19 May 2012

Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.

scientific article

Erratum to: SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

scientific article published on 12 May 2016

Event Rates in Trials of Patients With Type 2 Diabetes

scientific article published in The Journal of the American Medical Association

Ezetimibe: Likely to Be Beneficial For All

scientific article published on 01 April 2018

Falling Cardiovascular Mortality in Heart Failure With Reduced Ejection Fraction and Implications for Clinical Trials.

scientific article published on August 2015

Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up

scientific article

Genetic insights into statin-associated diabetes risk

scientific article published on April 2016

HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?

scientific article published in The Lancet

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

scientific article published on 24 September 2014

HbA1c in type 2 diabetes diagnostic criteria: addressing the right questions to move the field forwards

scientific article published on 8 March 2012

HbA1c: a useful cardiovascular risk marker in those without diabetes?

scientific article published on 11 September 2010

How to measure renal function in clinical practice: eating cooked meat alters serum creatinine concentration and eGFR significantly

scientific article published in November 2006

Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review

scientific article

Intensive glucose lowering treatment in type 2 diabetes

scientific article published on 26 July 2011

Interpretation of the evidence for the efficacy and safety of statin therapy

scientific article

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data

scientific article

Lipid-modifying therapies and risk of pancreatitis: a meta-analysis

scientific article published in August 2012

Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence

scientific article published on 03 December 2008

Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data

scientific article

Mendelian randomisation study for statin treatment – Authors' reply

scientific article published in The Lancet

Metabolic syndrome, dysglycaemia and vascular disease: making sense of the evidence

scientific article published on December 2007

Metabolic syndrome: collapsing under its own weight?

scientific article published in May 2009

Metformin Therapy and Circulating NT-proBNP Levels: The CAMERA Trial

scientific article published on 06 June 2016

Metformin and lactic acidosis. Metformin: framed again?

scientific article published on 23 December 2009

Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial.

scientific article published on 7 November 2013

Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials

scientific article published on 14 September 2015

Non-alcoholic fatty liver disease

scientific article

Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations

scientific article published on September 2008

PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study

scientific article published on 28 November 2016

PCSK9 inhibition: the dawn of a new age in cholesterol lowering?

scientific article published on 26 December 2016

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9

scientific article published on 29 October 2019

Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial

scientific article published on 12 April 2015

Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies

scientific article

Prediction of Cardiovascular Disease Risk by Cardiac Biomarkers in 2 United Kingdom Cohort Studies: Does Utility Depend on Risk Thresholds For Treatment?

scientific article

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial

scientific article

Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program

scientific article published on 05 February 2009

Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial

scientific article published on 30 July 2013

Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study

scientific article

Reducing cardiovascular risk in type 2 diabetes mellitus

Reply

Research digest

scientific article published on 09 July 2016

Research digest

scientific article published on 07 December 2016

Research digest: CV trials in diabetes-looking ahead

scientific article published on 01 October 2018

Research digest: NAFLD in the spotlight

scientific article published on 30 July 2016

Research digest: SGLT2 inhibition in kidney and liver disease

scientific article published on 01 June 2019

Research digest: assessment and risks of obesity

scientific article published on 01 June 2018

Research digest: cardiac biomarkers for risk prediction

scientific article published on 12 October 2016

Research digest: genetics in cardiometabolic disease

scientific article published on 01 December 2018

Research digest: heart failure in diabetes comes into focus

scientific article published on 01 August 2018

Research digest: hypoglycaemia and glucose variability

scientific article published on 8 November 2017

Research digest: more cardiovascular outcome trials in diabetes

scientific article published on 09 August 2017

Research digest: new insights into established risk pathways

scientific article published on 01 April 2019

Research digest: prediabetes definitions and diabetes prevention

scientific article published on 09 February 2017

Research digest: progress in microvascular complications

scientific article published in February 2018

Research digest: the risks of type 2 diabetes at a young age

scientific article published on 05 April 2017

Research digest: topical trials in thyroid disease

scientific article published on 07 June 2017

Research digest: updates on diabetes in pregnancy

scientific article published on 01 April 2018

Research digest: vitamin D supplementation

scientific article published on 01 February 2019

Research digest: weight loss to prevent and treat diabetes

scientific article published in October 2016

Reverse Causality in Cardiovascular Epidemiological Research: More Common Than Imagined?

scientific article published on 01 June 2017

Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial

scientific article

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

scientific article

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

scientific article

Screening for diabetes in patients with cardiovascular disease: HbA1c trumps oral glucose tolerance testing

scientific article

Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association

scientific article published on 01 February 2019

Statin therapy and new-onset diabetes: A cause for concern? ⬇️

scientific article published on March 22, 2012

Statins and new-onset diabetes—the important questions ⬇️

scientific article published on February 14, 2012

Statins and risk of incident diabetes – Authors' reply

scientific article published in The Lancet

Statins and the risk of new-onset diabetes: a review of recent evidence

scientific article published on December 2011

Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes.

scientific article published on 13 November 2016

The Role of Emerging Risk Factors in Cardiovascular Outcomes

scientific article

The case for diabetes screening: ADDITION-Europe

scientific article published on 24 June 2011

The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials

scientific article

The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome

scientific article published on 28 June 2008

The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective

scientific article

The incremental prognostic and clinical value of multiple novel biomarkers in heart failure

scientific article published on 25 April 2016

The influence of a cooked-meat meal on estimated glomerular filtration rate

scientific article published in January 2007

The insulin resistance syndrome

The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes

scientific article published on 17 November 2011

The new pooled cohort equations risk calculator

scientific article published on 04 February 2015

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

scientific article published on 25 October 2018

Tightening our understanding of intensive glycaemic control

scientific article published on 30 March 2017

Treatment of severe hypertriglyceridaemia

scientific article published on 20 March 2014

Triglyceride levels, pancreatitis and choice of lipid-modifying therapy

scientific article published on 01 March 2013

Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis?

scientific article published on April 2007

List of works by David Preiss

A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design

Ambient temperature and pseudohyperkalaemia

Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future

Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes

Biochemistry laboratories should routinely report non-HDL-cholesterol

Body Mass Index and Risk of Nonalcoholic Fatty Liver Disease: Two Electronic Health Record Prospective Studies

Cardiac Troponin T and Troponin I in the General Population

Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies?

Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study

Choice of medical therapy to lower triglycerides in those at risk of pancreatitis

Cholesterol- and blood-pressure-lowering drug use for secondary cardiovascular prevention in 2004-2013 Europe

Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week

Classification of reported statin intolerance

Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ej

Combined Free Light Chains Are Novel Predictors of Prognosis in Heart Failure.

Combined cardiovascular and diabetes risk assessment in primary care

Comparison between High-Sensitivity Cardiac Troponin T and Cardiac Troponin I in a Large General Population Cohort

Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.

Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction

Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up

Diabetic microvascular complications as simple indicators of risk for cardiovascular outcomes and heart failure

Diagnosing unsuspected hypopituitarism in adults from suggestive thyroid function test results

Do statins reduce microvascular complications in diabetes?

Does the LDL Receptor Play a Role in the Risk of Developing Type 2 Diabetes?

Effect of Evolocumab on Lipoprotein Particles

Effect of Rosuvastatin on Fatigue in Patients With Heart Failure

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

Effect of metformin therapy on circulating amino acids in a randomized trial: the CAMERA study

Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis

Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial

Emerging therapeutic approaches to treat dyslipidemia

Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).

Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.

Erratum to: SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

Event Rates in Trials of Patients With Type 2 Diabetes

Ezetimibe: Likely to Be Beneficial For All

Falling Cardiovascular Mortality in Heart Failure With Reduced Ejection Fraction and Implications for Clinical Trials.

Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up

Genetic insights into statin-associated diabetes risk

HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

HbA1c in type 2 diabetes diagnostic criteria: addressing the right questions to move the field forwards

HbA1c: a useful cardiovascular risk marker in those without diabetes?

How to measure renal function in clinical practice: eating cooked meat alters serum creatinine concentration and eGFR significantly

Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review

Intensive glucose lowering treatment in type 2 diabetes

Interpretation of the evidence for the efficacy and safety of statin therapy

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data

Lipid-modifying therapies and risk of pancreatitis: a meta-analysis

Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence

Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data

Mendelian randomisation study for statin treatment – Authors' reply

Metabolic syndrome, dysglycaemia and vascular disease: making sense of the evidence

Metabolic syndrome: collapsing under its own weight?

Metformin Therapy and Circulating NT-proBNP Levels: The CAMERA Trial

Metformin and lactic acidosis. Metformin: framed again?

Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial.

Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials

Non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations

PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study

PCSK9 inhibition: the dawn of a new age in cholesterol lowering?

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9

Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial

Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies

Prediction of Cardiovascular Disease Risk by Cardiac Biomarkers in 2 United Kingdom Cohort Studies: Does Utility Depend on Risk Thresholds For Treatment?

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial

Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program

Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial

Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study

Reducing cardiovascular risk in type 2 diabetes mellitus

Reply

Research digest

Research digest

Research digest: CV trials in diabetes-looking ahead

Research digest: NAFLD in the spotlight

Research digest: SGLT2 inhibition in kidney and liver disease